Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone

We evaluated an African American woman referred in 1986 at age 33 years because of renal potassium and calcium wasting and chronic hip pain. She presented normotensive, hypokalemic, hypocalcemic, normophosphatemic, and hypercalciuric. Marked hyperparathyroidism was evident. Urinary cyclic adenosine...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of bone and mineral research 2013-03, Vol.28 (3), p.700-708
Hauptverfasser: Park‐Sigal, Jennifer, Don, Burl R, Porzig, Anne, Recker, Robert, Griswold, Virginia, Sebastian, Anthony, Duh, Quan‐Yang, Portale, Anthony A, Shoback, Dolores, Schambelan, Morris
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 708
container_issue 3
container_start_page 700
container_title Journal of bone and mineral research
container_volume 28
creator Park‐Sigal, Jennifer
Don, Burl R
Porzig, Anne
Recker, Robert
Griswold, Virginia
Sebastian, Anthony
Duh, Quan‐Yang
Portale, Anthony A
Shoback, Dolores
Schambelan, Morris
description We evaluated an African American woman referred in 1986 at age 33 years because of renal potassium and calcium wasting and chronic hip pain. She presented normotensive, hypokalemic, hypocalcemic, normophosphatemic, and hypercalciuric. Marked hyperparathyroidism was evident. Urinary cyclic adenosine monophosphate (cAMP) excretion did not increase in response to parathyroid hormone (PTH) infusion, indicating renal resistance to PTH. X‐rays and bone biopsy revealed severe osteitis fibrosa cystica, confirming skeletal responsiveness to PTH. Renal potassium wasting, suppressed plasma renin activity, and elevated plasma and urinary aldosterone levels accompanied her hypokalemia, suggesting primary hyperaldosteronism. Hypokalemia resolved with spironolactone and, when combined with dietary sodium restriction, urinary calcium excretion fell and hypocalcemia improved, in accord with the known positive association between sodium intake and calcium excretion. Calcitriol and oral calcium supplements did not suppress the chronic hyperparathyroidism nor did they reduce aldosterone levels. Over time, hyperparathyroid bone disease progressed with pathologic fractures and persistent pain. In 2004, PTH levels increased further in association with worsening chronic kidney disease. Eventually hypercalcemia and hypertension developed. Localizing studies in 2005 suggested a left inferior parathyroid tumor. After having consistently declined, the patient finally agreed to neck exploration in January 2009. Four hyperplastic parathyroid glands were removed, followed immediately by severe hypocalcemia, attributed to “hungry bone syndrome” and hypoparathyroidism, which required prolonged hospitalization, calcium infusions, and oral calcitriol. Although her bone pain resolved, hyperaldosteronism persisted. © 2013 American Society for Bone and Mineral Research.
doi_str_mv 10.1002/jbmr.1791
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1323813829</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2892561451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4211-13d503c52136527d99ce8eb2cd5f1a87104307097879c47177c39b7f512aded93</originalsourceid><addsrcrecordid>eNqN0U1r3DAQBmBRWpJtmkP_QBD0kh6caCTZko5J6CcphX6cjVaa7WqxJUfyJuy9P7zeOC2lEOhlxMCjF4aXkJfAzoAxfr5Z9vkMlIEnZAE1F5VsNDwlC6a1rJgUcEiel7JhjDV10xyQQy6Yksw0C_LzK95iRrreDZid7Rz2wc3bYLMd17ucgg-lp36CXRpC_EFDpJYOdgwYR3oXxvX8wXY-lRFzintvo6cZo-2mWUIZbXRIx0T_iqXrlPsU8QV5trJdweOH94h8f_vm29X76vrzuw9XF9eVkxygAuFrJlzNQTQ1V94YhxqX3Pl6BVYrmE5lihmllXFSgVJOmKVa1cCtR2_EETmdc4ecbrZYxrYPxWHX2YhpW1oQXGgQmv8H5VobIyXoib76h27SNk-H3ytltGyaelKvZ-VyKiXjqh1y6G3etcDafYvtvsV23-JkTx4St8se_R_5u7YJnM_gLnS4ezyp_Xj56ct95C9NGKjM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1287984665</pqid></control><display><type>article</type><title>Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Park‐Sigal, Jennifer ; Don, Burl R ; Porzig, Anne ; Recker, Robert ; Griswold, Virginia ; Sebastian, Anthony ; Duh, Quan‐Yang ; Portale, Anthony A ; Shoback, Dolores ; Schambelan, Morris</creator><creatorcontrib>Park‐Sigal, Jennifer ; Don, Burl R ; Porzig, Anne ; Recker, Robert ; Griswold, Virginia ; Sebastian, Anthony ; Duh, Quan‐Yang ; Portale, Anthony A ; Shoback, Dolores ; Schambelan, Morris</creatorcontrib><description>We evaluated an African American woman referred in 1986 at age 33 years because of renal potassium and calcium wasting and chronic hip pain. She presented normotensive, hypokalemic, hypocalcemic, normophosphatemic, and hypercalciuric. Marked hyperparathyroidism was evident. Urinary cyclic adenosine monophosphate (cAMP) excretion did not increase in response to parathyroid hormone (PTH) infusion, indicating renal resistance to PTH. X‐rays and bone biopsy revealed severe osteitis fibrosa cystica, confirming skeletal responsiveness to PTH. Renal potassium wasting, suppressed plasma renin activity, and elevated plasma and urinary aldosterone levels accompanied her hypokalemia, suggesting primary hyperaldosteronism. Hypokalemia resolved with spironolactone and, when combined with dietary sodium restriction, urinary calcium excretion fell and hypocalcemia improved, in accord with the known positive association between sodium intake and calcium excretion. Calcitriol and oral calcium supplements did not suppress the chronic hyperparathyroidism nor did they reduce aldosterone levels. Over time, hyperparathyroid bone disease progressed with pathologic fractures and persistent pain. In 2004, PTH levels increased further in association with worsening chronic kidney disease. Eventually hypercalcemia and hypertension developed. Localizing studies in 2005 suggested a left inferior parathyroid tumor. After having consistently declined, the patient finally agreed to neck exploration in January 2009. Four hyperplastic parathyroid glands were removed, followed immediately by severe hypocalcemia, attributed to “hungry bone syndrome” and hypoparathyroidism, which required prolonged hospitalization, calcium infusions, and oral calcitriol. Although her bone pain resolved, hyperaldosteronism persisted. © 2013 American Society for Bone and Mineral Research.</description><identifier>ISSN: 0884-0431</identifier><identifier>EISSN: 1523-4681</identifier><identifier>DOI: 10.1002/jbmr.1791</identifier><identifier>PMID: 23074096</identifier><identifier>CODEN: JBMREJ</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aldosterone ; Biopsy ; Bone ; Calcitriol ; Calcium - metabolism ; Cyclic AMP ; Excretion ; Female ; Fractures ; Hip ; Homeostasis ; Humans ; HYPERALDOSTERONISM ; Hypercalcemia ; Hypercalcemia - complications ; Hypercalcemia - physiopathology ; Hyperparathyroidism ; Hyperparathyroidism - complications ; Hyperparathyroidism - physiopathology ; HYPOCALCEMIA ; Hypokalemia ; Kidney - drug effects ; Kidney - physiopathology ; Osteitis ; OSTEITIS FIBROSA CYSTICA ; Pain ; Parathyroid ; PARATHYROID HORMONE ; Parathyroid Hormone - administration &amp; dosage ; Potassium ; Potassium - metabolism ; PSEUDOHYPOPARATHYROIDISM ; Sodium ; Tumors</subject><ispartof>Journal of bone and mineral research, 2013-03, Vol.28 (3), p.700-708</ispartof><rights>Copyright © 2013 American Society for Bone and Mineral Research</rights><rights>Copyright © 2013 American Society for Bone and Mineral Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4211-13d503c52136527d99ce8eb2cd5f1a87104307097879c47177c39b7f512aded93</citedby><cites>FETCH-LOGICAL-c4211-13d503c52136527d99ce8eb2cd5f1a87104307097879c47177c39b7f512aded93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjbmr.1791$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjbmr.1791$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23074096$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park‐Sigal, Jennifer</creatorcontrib><creatorcontrib>Don, Burl R</creatorcontrib><creatorcontrib>Porzig, Anne</creatorcontrib><creatorcontrib>Recker, Robert</creatorcontrib><creatorcontrib>Griswold, Virginia</creatorcontrib><creatorcontrib>Sebastian, Anthony</creatorcontrib><creatorcontrib>Duh, Quan‐Yang</creatorcontrib><creatorcontrib>Portale, Anthony A</creatorcontrib><creatorcontrib>Shoback, Dolores</creatorcontrib><creatorcontrib>Schambelan, Morris</creatorcontrib><title>Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone</title><title>Journal of bone and mineral research</title><addtitle>J Bone Miner Res</addtitle><description>We evaluated an African American woman referred in 1986 at age 33 years because of renal potassium and calcium wasting and chronic hip pain. She presented normotensive, hypokalemic, hypocalcemic, normophosphatemic, and hypercalciuric. Marked hyperparathyroidism was evident. Urinary cyclic adenosine monophosphate (cAMP) excretion did not increase in response to parathyroid hormone (PTH) infusion, indicating renal resistance to PTH. X‐rays and bone biopsy revealed severe osteitis fibrosa cystica, confirming skeletal responsiveness to PTH. Renal potassium wasting, suppressed plasma renin activity, and elevated plasma and urinary aldosterone levels accompanied her hypokalemia, suggesting primary hyperaldosteronism. Hypokalemia resolved with spironolactone and, when combined with dietary sodium restriction, urinary calcium excretion fell and hypocalcemia improved, in accord with the known positive association between sodium intake and calcium excretion. Calcitriol and oral calcium supplements did not suppress the chronic hyperparathyroidism nor did they reduce aldosterone levels. Over time, hyperparathyroid bone disease progressed with pathologic fractures and persistent pain. In 2004, PTH levels increased further in association with worsening chronic kidney disease. Eventually hypercalcemia and hypertension developed. Localizing studies in 2005 suggested a left inferior parathyroid tumor. After having consistently declined, the patient finally agreed to neck exploration in January 2009. Four hyperplastic parathyroid glands were removed, followed immediately by severe hypocalcemia, attributed to “hungry bone syndrome” and hypoparathyroidism, which required prolonged hospitalization, calcium infusions, and oral calcitriol. Although her bone pain resolved, hyperaldosteronism persisted. © 2013 American Society for Bone and Mineral Research.</description><subject>Adult</subject><subject>Aldosterone</subject><subject>Biopsy</subject><subject>Bone</subject><subject>Calcitriol</subject><subject>Calcium - metabolism</subject><subject>Cyclic AMP</subject><subject>Excretion</subject><subject>Female</subject><subject>Fractures</subject><subject>Hip</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>HYPERALDOSTERONISM</subject><subject>Hypercalcemia</subject><subject>Hypercalcemia - complications</subject><subject>Hypercalcemia - physiopathology</subject><subject>Hyperparathyroidism</subject><subject>Hyperparathyroidism - complications</subject><subject>Hyperparathyroidism - physiopathology</subject><subject>HYPOCALCEMIA</subject><subject>Hypokalemia</subject><subject>Kidney - drug effects</subject><subject>Kidney - physiopathology</subject><subject>Osteitis</subject><subject>OSTEITIS FIBROSA CYSTICA</subject><subject>Pain</subject><subject>Parathyroid</subject><subject>PARATHYROID HORMONE</subject><subject>Parathyroid Hormone - administration &amp; dosage</subject><subject>Potassium</subject><subject>Potassium - metabolism</subject><subject>PSEUDOHYPOPARATHYROIDISM</subject><subject>Sodium</subject><subject>Tumors</subject><issn>0884-0431</issn><issn>1523-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0U1r3DAQBmBRWpJtmkP_QBD0kh6caCTZko5J6CcphX6cjVaa7WqxJUfyJuy9P7zeOC2lEOhlxMCjF4aXkJfAzoAxfr5Z9vkMlIEnZAE1F5VsNDwlC6a1rJgUcEiel7JhjDV10xyQQy6Yksw0C_LzK95iRrreDZid7Rz2wc3bYLMd17ucgg-lp36CXRpC_EFDpJYOdgwYR3oXxvX8wXY-lRFzintvo6cZo-2mWUIZbXRIx0T_iqXrlPsU8QV5trJdweOH94h8f_vm29X76vrzuw9XF9eVkxygAuFrJlzNQTQ1V94YhxqX3Pl6BVYrmE5lihmllXFSgVJOmKVa1cCtR2_EETmdc4ecbrZYxrYPxWHX2YhpW1oQXGgQmv8H5VobIyXoib76h27SNk-H3ytltGyaelKvZ-VyKiXjqh1y6G3etcDafYvtvsV23-JkTx4St8se_R_5u7YJnM_gLnS4ezyp_Xj56ct95C9NGKjM</recordid><startdate>201303</startdate><enddate>201303</enddate><creator>Park‐Sigal, Jennifer</creator><creator>Don, Burl R</creator><creator>Porzig, Anne</creator><creator>Recker, Robert</creator><creator>Griswold, Virginia</creator><creator>Sebastian, Anthony</creator><creator>Duh, Quan‐Yang</creator><creator>Portale, Anthony A</creator><creator>Shoback, Dolores</creator><creator>Schambelan, Morris</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TS</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201303</creationdate><title>Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone</title><author>Park‐Sigal, Jennifer ; Don, Burl R ; Porzig, Anne ; Recker, Robert ; Griswold, Virginia ; Sebastian, Anthony ; Duh, Quan‐Yang ; Portale, Anthony A ; Shoback, Dolores ; Schambelan, Morris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4211-13d503c52136527d99ce8eb2cd5f1a87104307097879c47177c39b7f512aded93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aldosterone</topic><topic>Biopsy</topic><topic>Bone</topic><topic>Calcitriol</topic><topic>Calcium - metabolism</topic><topic>Cyclic AMP</topic><topic>Excretion</topic><topic>Female</topic><topic>Fractures</topic><topic>Hip</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>HYPERALDOSTERONISM</topic><topic>Hypercalcemia</topic><topic>Hypercalcemia - complications</topic><topic>Hypercalcemia - physiopathology</topic><topic>Hyperparathyroidism</topic><topic>Hyperparathyroidism - complications</topic><topic>Hyperparathyroidism - physiopathology</topic><topic>HYPOCALCEMIA</topic><topic>Hypokalemia</topic><topic>Kidney - drug effects</topic><topic>Kidney - physiopathology</topic><topic>Osteitis</topic><topic>OSTEITIS FIBROSA CYSTICA</topic><topic>Pain</topic><topic>Parathyroid</topic><topic>PARATHYROID HORMONE</topic><topic>Parathyroid Hormone - administration &amp; dosage</topic><topic>Potassium</topic><topic>Potassium - metabolism</topic><topic>PSEUDOHYPOPARATHYROIDISM</topic><topic>Sodium</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park‐Sigal, Jennifer</creatorcontrib><creatorcontrib>Don, Burl R</creatorcontrib><creatorcontrib>Porzig, Anne</creatorcontrib><creatorcontrib>Recker, Robert</creatorcontrib><creatorcontrib>Griswold, Virginia</creatorcontrib><creatorcontrib>Sebastian, Anthony</creatorcontrib><creatorcontrib>Duh, Quan‐Yang</creatorcontrib><creatorcontrib>Portale, Anthony A</creatorcontrib><creatorcontrib>Shoback, Dolores</creatorcontrib><creatorcontrib>Schambelan, Morris</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Physical Education Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of bone and mineral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park‐Sigal, Jennifer</au><au>Don, Burl R</au><au>Porzig, Anne</au><au>Recker, Robert</au><au>Griswold, Virginia</au><au>Sebastian, Anthony</au><au>Duh, Quan‐Yang</au><au>Portale, Anthony A</au><au>Shoback, Dolores</au><au>Schambelan, Morris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone</atitle><jtitle>Journal of bone and mineral research</jtitle><addtitle>J Bone Miner Res</addtitle><date>2013-03</date><risdate>2013</risdate><volume>28</volume><issue>3</issue><spage>700</spage><epage>708</epage><pages>700-708</pages><issn>0884-0431</issn><eissn>1523-4681</eissn><coden>JBMREJ</coden><abstract>We evaluated an African American woman referred in 1986 at age 33 years because of renal potassium and calcium wasting and chronic hip pain. She presented normotensive, hypokalemic, hypocalcemic, normophosphatemic, and hypercalciuric. Marked hyperparathyroidism was evident. Urinary cyclic adenosine monophosphate (cAMP) excretion did not increase in response to parathyroid hormone (PTH) infusion, indicating renal resistance to PTH. X‐rays and bone biopsy revealed severe osteitis fibrosa cystica, confirming skeletal responsiveness to PTH. Renal potassium wasting, suppressed plasma renin activity, and elevated plasma and urinary aldosterone levels accompanied her hypokalemia, suggesting primary hyperaldosteronism. Hypokalemia resolved with spironolactone and, when combined with dietary sodium restriction, urinary calcium excretion fell and hypocalcemia improved, in accord with the known positive association between sodium intake and calcium excretion. Calcitriol and oral calcium supplements did not suppress the chronic hyperparathyroidism nor did they reduce aldosterone levels. Over time, hyperparathyroid bone disease progressed with pathologic fractures and persistent pain. In 2004, PTH levels increased further in association with worsening chronic kidney disease. Eventually hypercalcemia and hypertension developed. Localizing studies in 2005 suggested a left inferior parathyroid tumor. After having consistently declined, the patient finally agreed to neck exploration in January 2009. Four hyperplastic parathyroid glands were removed, followed immediately by severe hypocalcemia, attributed to “hungry bone syndrome” and hypoparathyroidism, which required prolonged hospitalization, calcium infusions, and oral calcitriol. Although her bone pain resolved, hyperaldosteronism persisted. © 2013 American Society for Bone and Mineral Research.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>23074096</pmid><doi>10.1002/jbmr.1791</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0884-0431
ispartof Journal of bone and mineral research, 2013-03, Vol.28 (3), p.700-708
issn 0884-0431
1523-4681
language eng
recordid cdi_proquest_miscellaneous_1323813829
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Aldosterone
Biopsy
Bone
Calcitriol
Calcium - metabolism
Cyclic AMP
Excretion
Female
Fractures
Hip
Homeostasis
Humans
HYPERALDOSTERONISM
Hypercalcemia
Hypercalcemia - complications
Hypercalcemia - physiopathology
Hyperparathyroidism
Hyperparathyroidism - complications
Hyperparathyroidism - physiopathology
HYPOCALCEMIA
Hypokalemia
Kidney - drug effects
Kidney - physiopathology
Osteitis
OSTEITIS FIBROSA CYSTICA
Pain
Parathyroid
PARATHYROID HORMONE
Parathyroid Hormone - administration & dosage
Potassium
Potassium - metabolism
PSEUDOHYPOPARATHYROIDISM
Sodium
Tumors
title Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T16%3A50%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20hypercalcemic%20hyperparathyroidism%20developing%20in%20a%20patient%20with%20hyperaldosteronism%20and%20renal%20resistance%20to%20parathyroid%20hormone&rft.jtitle=Journal%20of%20bone%20and%20mineral%20research&rft.au=Park%E2%80%90Sigal,%20Jennifer&rft.date=2013-03&rft.volume=28&rft.issue=3&rft.spage=700&rft.epage=708&rft.pages=700-708&rft.issn=0884-0431&rft.eissn=1523-4681&rft.coden=JBMREJ&rft_id=info:doi/10.1002/jbmr.1791&rft_dat=%3Cproquest_cross%3E2892561451%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1287984665&rft_id=info:pmid/23074096&rfr_iscdi=true